Format

Send to

Choose Destination
Gastroenterology. 2016 Jan;150(1):82-85.e4. doi: 10.1053/j.gastro.2015.09.011. Epub 2015 Sep 25.

Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.

Author information

1
Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York.
2
Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.
3
Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York.
4
Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. Electronic address: Darius.Moradpour@chuv.ch.
5
Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. Electronic address: Jerome.Gouttenoire@chuv.ch.

Abstract

Infection with hepatitis E virus genotype 3 may result in chronic hepatitis in immunocompromised patients. Reduction of immunosuppression or treatment with ribavirin or pegylated interferon-α can result in viral clearance. However, safer and more effective treatment options are needed. Here, we show that sofosbuvir inhibits the replication of hepatitis E virus genotype 3 both in subgenomic replicon systems as well as a full-length infectious clone. Moreover, the combination of sofosbuvir and ribavirin results in an additive antiviral effect. Sofosbuvir may be considered as an add-on therapy to ribavirin for the treatment of chronic hepatitis E in immunocompromised patients.

KEYWORDS:

Antiviral; Chronic Hepatitis; Immunosuppression; Polymerase Inhibitor

PMID:
26408347
DOI:
10.1053/j.gastro.2015.09.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center